This is a preview of subscription content, log in via an institution to check access.
Notes
ADalimumab ACTemrA
The study was supported by a contract from Genentech, Inc.
American College of Rheumatology
Reference
Carlson JJ, et al. Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis. Value in Health 18: 173-9, No. 2, Mar 2015. Available from: URL: http://doi.org/10.1016/j.jval.2014.10.013
Rights and permissions
About this article
Cite this article
Tocilizumab monotherapy worth its cost in severe active RA. PharmacoEcon Outcomes News 724, 26 (2015). https://doi.org/10.1007/s40274-015-2004-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-2004-2